Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Five‐year follow‐up of incretin‐based therapy in a patient with KCNJ11‐related permanent neonatal diabetes: Achieving insulin discontinuation and sulfonylurea reduction
Saved in:
| Published in: | Journal of Diabetes Investigation |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Five‐year follow‐up of incretin‐based therapy in a patient with KCNJ11‐related permanent neonatal diabetes: Achieving insulin discontinuation and sulfonylurea reduction
- c‐Jun N‐terminal kinase 3 as a permissive regulator of β‐cell incretin responsiveness
- Recent advances in incretin biology and therapeutics: From glucose‐dependent insulinotropic polypeptide reappraisal to next‐generation agonists
- Efficacy and Safety of Insulin Efsitora Versus Degludec in Adults with Type 2 Diabetes Who Are Insulin-Naïve: Japan Subgroup Analysis of QWINT-2
- Role of the UHRF1–KLHL6–CORO2B axis in obesity‐related insulin resistance
- Optimizing Type 2 Diabetes Management in Iraq: Expert Consensus on Initiation and Intensification of Insulin-Based Treatment Options
- Correspondence: Effects of short‐term tofogliflozin treatment on insulin secretory capacity in type 2 diabetes: Insights and future directions